{
  "id": "ed9f0c26964ca2a6",
  "title": "1 in 4 metastatic breast cancer patients treated with Novartis Kisqali\u00ae remain progression - free beyond 4 years",
  "description": "20251209T231500Z",
  "content": "",
  "source": "portal.sina.com.hk",
  "source_url": "https://portal.sina.com.hk/finance/finance-globenewswire/globenewswire/2025/12/09/1404099/1-in-4-metastatic-breast-cancer-patients-treated-with-novartis-kisqali-remain-progression-free-beyond-4-years/",
  "published_at": "20251209T231500Z",
  "fetched_at": "2025-12-10T00:22:54.894572+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "ai"
  ],
  "location": "Hong Kong",
  "raw_data": {
    "url": "https://portal.sina.com.hk/finance/finance-globenewswire/globenewswire/2025/12/09/1404099/1-in-4-metastatic-breast-cancer-patients-treated-with-novartis-kisqali-remain-progression-free-beyond-4-years/",
    "url_mobile": "",
    "title": "1 in 4 metastatic breast cancer patients treated with Novartis Kisqali\u00ae remain progression - free beyond 4 years",
    "seendate": "20251209T231500Z",
    "socialimage": "https://ml-eu.globenewswire.com/media/ODY2MDFiMTItNjc0MS00NjQzLWJmYWItZDhhNzFmMzE3ODBiLTEwMTQwMjQtMjAyNS0xMi0wOS1lbg==/tiny/Novartis-Pharma-AG.png",
    "domain": "portal.sina.com.hk",
    "language": "English",
    "sourcecountry": "Hong Kong"
  }
}